Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Medical Literature

Adding Stereotactic Body Radiotherapy to Immunotherapy for Early-Stage NSCLC

News

Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC

Medical Literature

Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?

Medical Literature

Nab-paclitaxel Monotherapy in EGFR-Mutated Advanced Lung Cancer

Medical Literature

Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?

News

Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer

News

Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?

Egbert F. Smit, MD, PhD, on Clinical Implications of Fam-trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Vamsidhar Velcheti, MD, on CodeBreaK 100: Update on Use of Sotorasib in NSCLC

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

View More

More

News

RATIONALE 303 Update on Tislelizumab Versus Docetaxel in Advanced NSCLC

ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer

$20 Million Donation to MSK to Support Lung Cancer Research

Sotorasib Receives Approval for NSCLC With KRAS G12C Mutations

AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC

FDA Accepts Submission for Sintilimab in Combination With Pemetrexed/Platinum Chemotherapy in NSCLC

AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer

Does Pembrolizumab Plus Chemotherapy–Induced Pneumonitis Impact Survival Outcomes in NSCLC?

View More

Advertisement

Published

Medical Literature

Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

Brigatinib in Patients With Crizotinib-Refractory ALK-Positive NSCLC

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

View More

Ongoing

CE Activities

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Novel and Emerging Therapeutic Strategies in the Management of Non–Small Cell Lung Cancer

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Consensus or Controversy? Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.